![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The net proceeds will be used to further develop DeepCure’s cutting-edge technology for small molecule drug discovery, and to advance its immunology and inflammation pipeline towards clinical trials.
Lead Product(s): Brd4
Therapeutic Area: Immunology Product Name: Brd4
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: IAG Capital Partners
Deal Size: $24.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 11, 2024